Insulin degludec/liraglutide

Drug Profile

Insulin degludec/liraglutide

Alternative Names: GLP-1 and basal insulin combination; IDegLira; Insulin degludec/Victoza; Liraglutide/insulin degludec; Liraglutide/NN 1250; Liraglutide/Tresiba; NN 1250/liraglutide; NN-9068; Tresiba/liraglutide; Victoza/insulin degludec; Xultophy

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Novo Nordisk
  • Class Antihyperglycaemics; Glucagon-like peptides; Insulins; Pancreatic hormones
  • Mechanism of Action Glucagon like peptide 1 receptor agonists; Glucagon receptor antagonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 03 May 2017 Launched for Type-2 diabetes mellitus in USA (SC)
  • 03 May 2017 The US approved label for insulin degludec/liraglutide carries a black boxed warning regarding the potential risk of thyroid C-cell tumours
  • 02 Dec 2016 Efficacy data from the phase IIIb DUAL VII trial in Type-2 diabetes mellitus released by Novo Nordisk
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top